Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CEL-SCI’s immunomodulator effective against hepatitis B
This effect in a mouse model was seen within 14 days, most pronounced with a single dose of CEL-1000 at day 0 and resulted in up to a
This effect in a mouse model was seen within 14 days, most pronounced with a single dose of CEL-1000 at day 0 and resulted in up to a
In preclinical studies, REP3123 was superior to two agents widely used to treat C. difficile infections, vancomycin and metronidazole, in preventing the organism from forming spores. The study
Hi-Tech’s ciclopirox topical solution is the generic equivalent of Dermik Laboratories’ nail fungus treatment penlac topical solution, which had sales of $87 million in 2006 based on IMS
Under the terms of the agreement, Adams will receive an exclusive, royalty- bearing license from Lipocine to develop and market multiple prescription adult cough products in North America.
The Phase II, double-blind, placebo-controlled, multi-center trial includes 124 menopausal women with recurrent, moderate to severe hot flashes and is being conducted at eight sites in the US.
Preliminary findings from a Phase II study with intramuscular (im) injection of peramivir, the company’s product candidate for the treatment of seasonal and life-threatening influenza, found that the
In total, $65 million was paid by Hologic in shares of Hologic’s common stock valued at $54.222 per share and $5 million was paid in cash. Hologic will
Cogenics developed the proprietary genotyping service called the Pain Research Panel, which enables the investigation of key target genes involved in pain as well as those that mediate
As a result, Cambridge, Massachusetts-based Alnylam has rescinded all grants of its intellectual property related to current and future Merck development programs, including the partnership’s former co-development programs.
The nine-month opposition period for the patent expired on August 8, 2007. The patent also has been granted in several other countries outside of Europe. Intellect Neurosciences is